New opioid aims to ease pain without slowing digestion
NCT ID NCT07307495
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a new painkiller called oliceridine fumarate can control pain after lumbar spine surgery while helping the gut recover faster. Standard opioids often cause constipation and slow digestion. The trial will compare oliceridine to the usual drug sufentanil in 428 adults undergoing back surgery. Researchers will measure how quickly patients can eat solid food and pass gas or have a bowel movement within 24 to 48 hours after surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
oliceridine fumarate
What this could lead to
If it works, this could offer a painkiller option that causes less constipation and helps the gut recover faster after surgery.
What could go wrong
This is an early-stage trial with no phase assigned, so results are uncertain. The drug may not prove better than existing options, and side effects are still being studied.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OLICERIDINE FUMARATE are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••